Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein
- 31 May 2004
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 40 (8) , 1269-1274
- https://doi.org/10.1016/j.ejca.2004.01.024
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivoJournal of Clinical Investigation, 2002
- Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patientsBritish Journal of Cancer, 2001
- Phase I Study of Paclitaxel in Combination With a Multidrug Resistance Modulator, PSC 833 (Valspodar), in Refractory MalignanciesJournal of Clinical Oncology, 2000
- Second Line Chemotherapy with Docetaxel in Patients with Recurrent Malignant Glioma: A Phase II StudyJournal of Neuro-Oncology, 2000
- Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoproteinBritish Journal of Cancer, 1998
- Complete in vivo reversal of P‐glycoprotein pump function in the blood‐brain barrier visualized with positron emission tomographyBritish Journal of Pharmacology, 1998
- Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.Journal of Clinical Investigation, 1997
- Altered Pharmacokinetics of Vinblastine in Mdr1a P-glycoprotein-Deficient MiceJNCI Journal of the National Cancer Institute, 1996
- Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugsPublished by Elsevier ,1994
- MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoringComputers in Biology and Medicine, 1992